Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

For companies in the process of listing (or already listed) on Nasdaq Copenhagen or Nasdaq Helsinki, please contact your local Relationship Manager to schedule training sessions. For companies to ...

Sampo plc, stock exchange release, 12 February 2025 at 8:30 am EET New Sampo shares issued in the share split registered with the Finnish Trade Register Sampo plc announced on 5 February 2025 the ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...

Company Release no. 20/2025 Copenhagen, Denmark, 5 February 2025With reference to Penneo A/S' ("Penneo") announcement of 5 February 2025 (no. 19/2025), regarding Penneo's Board of Directors' decision ...

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), has ...

Company Release no. 19/2025 Copenhagen, Denmark, 5 February 2025With reference to Penneo A/S' ("Penneo") announcement published today (no. 18/2025) regarding Visma Danmark Holding A/S' ("Visma") decis ...

Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by ...